Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging of Key Proteins

Barry J. (1), Ait-Belkacem R. (2), Hardesty W. (1), Benakli L. (2), Andonian C. (1), Licea-Perez H. (1), Stauber J. (2, 3), Castellino S. (1).

1) Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, United States
2) ImaBiotech SAS, Parc Eurasanté, 152 rue du Dr Yersin, 59120, Loos, France
3) ImaBiotech Corp, 44 Manning Rd, MA, 01821, Billerica, US.


The purpose of this study is to identify and visualize the spatial
distribution of proteins present in amyloid corneal deposits of TGFBI-CD patients using Mass Spectrometry Imaging (MSI) and compare it with healthy control cornea. Corneal Dystrophies (CD) constitute a group of genetically inherited protein aggregation disorders that affects different layers of the cornea. With accumulated protein deposition, the cornea becomes opaque with decreased visual acuity. CD affecting the stroma and Bowman’s membrane, is associated with mutations in transforming growth factor β-induced (TGFBI) gene.


MALDI-Mass Spectrometry Imaging (MSI) is performed on 2
patient corneas and is compared with 1 healthy control cornea using a
7T-MALDI-FTICR. Molecular images obtained are overlaid with congo-red stained sections to visualize the proteins associated with the corneal amyloid aggregates.


MALDI-MSI provides a relative abundance and two dimensional
spatial protein signature of key proteins (TGFBIp, Apolipoprotein A-I,
Apolipoprotein A-IV, Apolipoprotein E, Kaliocin-1, Pyruvate Kinase and Ras related protein Rab-10) in the patient deposits compared to the control. This is the first report of the anatomical localization of key proteins on corneal tissue section from CD patients. This may provide insight in understanding the mechanism of amyloid fibril formation in TGFBI-corneal dystrophy.

Download it

Search news